← Ablatotech Vitals
Urology EvidenceDigest

Integration of Liquid Biopsy in Monitoring Urothelial Carcinoma Progression

Urology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 6, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Liquid biopsy technologies analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in plasma and urine offer promising, minimally invasive tools for monitoring urothelial carcinoma progression. Recent advances integrating multi-targeted urinary tumor DNA capture with machine learning algorithms have improved detection sensitivity and specificity. These approaches may complement or partially replace invasive cystoscopic surveillance, enabling earlier detection of recurrence and treatment resistance. However, standardization and validation in larger cohorts remain necessary before routine clinical implementation (Tang et al., 2026; Chaux et al., 2026).

Clinical bottom line

Liquid biopsy technologies analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in plasma and urine offer promising, minimally invasive tools for monitoring urothelial carcinoma progression. Recent advances integrating multi-targeted urinary tumor DNA capture with machine learning algorithms have improved detection sensitivity and specificity. These approaches may complement or partially replace invasive cystoscopic surveillance, enabling earlier detection of recurrence and treatment resistance. However, standardization and validation in larger cohorts remain necessary before routine clinical implementation (Tang et al., 2026; Chaux et al., 2026).

What the evidence shows

Tang et al. (2026) conducted a multicenter prospective study employing multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma. Their approach demonstrated high accuracy in identifying disease presence and progression, outperforming traditional cytology and single-marker assays.

Chaux et al. (2026) review the role of liquid biopsy in genitourinary cancers, emphasizing ctDNA’s utility as a predictive biomarker for treatment selection and resistance monitoring in urothelial carcinoma. They highlight its potential to guide personalized therapy by capturing tumor heterogeneity non-invasively.

Albers Acosta et al. (2025) discuss integrating advanced imaging with biomarker-based liquid biopsy, underscoring the complementary nature of these modalities in comprehensive disease monitoring.

Homayoun et al. (2026) optimized diagnostic thresholds for a keratin 17–based urine liquid biopsy assay, improving detection in patients presenting with hematuria, a common urothelial carcinoma symptom.

Arévalo et al. (2023) describe optimized isolation techniques for CTCs and tumor hybrid cells (THCs) from blood samples, facilitating real-time monitoring of tumor dynamics in urothelial carcinoma patients.

Zhang et al. (2025) report on next-generation sequencing (NGS)-based plasma and urine ctDNA profiling for longitudinal monitoring of bladder carcinoma in situ, demonstrating feasibility and correlation with clinical outcomes.

Li et al. (2026) review multiple urinary biomarkers’ research progress, highlighting their non-invasive diagnostic and prognostic potential in urothelial carcinoma.

Caveats and uncertainty

Most studies are early-phase or observational, with limited large-scale validation.

Heterogeneity in assay platforms, target genes, and bioinformatics pipelines complicates cross-study comparisons.

Sensitivity may be reduced in low tumor burden or upper tract disease.

Standardized protocols and thresholds for clinical decision-making are lacking.

Cost-effectiveness and reimbursement issues remain to be addressed.

Integration with existing surveillance protocols requires further clinical trials.

How this may change practice

Liquid biopsy could reduce reliance on invasive cystoscopy for surveillance, improving patient comfort and compliance.

Real-time molecular monitoring may enable earlier detection of recurrence and therapeutic resistance.

Personalized treatment adjustments guided by liquid biopsy biomarkers could improve outcomes.

Multimodal approaches combining imaging and liquid biopsy may enhance diagnostic accuracy.

Clinicians should stay informed about emerging assays and consider participation in validation studies.

Implementation will require multidisciplinary collaboration and infrastructure development.


References

  1. Tang C, et al. Liquid biopsy based on multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma: a multicenter prospective study. Int Urol Nephrol. 2026; DOI:10.1007/s11255-025-04813-7
  2. Chaux A, et al. Liquid biopsy in genitourinary cancers: circulating tumor DNA as a predictive biomarker for treatment selection and resistance monitoring. Exploration of Targeted Anti-tumor Therapy. 2026; DOI:10.37349/etat.2026.1002407
  3. Albers Acosta E, et al. Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer. Cancers. 2025; DOI:10.3390/cancers17193261
  4. Homayoun S, et al. Diagnostic threshold optimization of a keratin 17–based urine liquid biopsy assay for urothelial carcinoma detection in patients with hematuria. J Liquid Biopsy. 2026; DOI:10.1016/j.jlb.2026.100679
  5. Arévalo I, et al. Optimization of CTCs and THCs Isolation From Human Blood Based on Genesis Technology as a Strategy of Urothelial Carcinoma Monitoring. J Liquid Biopsy. 2023; DOI:10.1016/j.jlb.2023.100078
  6. Zhang R, et al. 550P NGS-based liquid biopsy for plasma and urine ctDNA profiling and longitudinal monitoring in bladder urothelial carcinoma in situ. Ann Oncol. 2025; DOI:10.1016/j.annonc.2025.10.445
  7. Li S, et al. Research progress and clinical translation prospects of multiple urinary biomarkers in non-invasive diagnosis of urothelial carcinoma. Front Oncol. 2026; DOI:10.3389/fonc.2026.1984066

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team